Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Documenti analoghi

• Response to “Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease”
  di: Tsubasa Tsutsumi, et al.
  Pubblicazione: (2026)
• Platelet Proteomics: A Glimpse Into Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis
  di: Iulia Minciuna, et al.
  Pubblicazione: (2025)
• Young Adults Are at Highest Risk of Liver Fibrosis and Mortality Associated With Steatotic Liver Disease With Metabolic Dysfunction and Alcohol Consumption
  di: Jesse Pustjens, et al.
  Pubblicazione: (2025)
• Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026
  di: Norio Akuta, et al.
  Pubblicazione: (2026)
• Extrahepatic Events in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and the Impact of Genetics and Alcohol Intake
  di: Tomomi Kogiso, et al.
  Pubblicazione: (2025)